Alembic Pharma receives USFDA EIR for Karakhadi API facility

The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.

Powered by Capital Market - Live News